RS52423B - THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT - Google Patents
THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING ITInfo
- Publication number
- RS52423B RS52423B RS20120327A RSP20120327A RS52423B RS 52423 B RS52423 B RS 52423B RS 20120327 A RS20120327 A RS 20120327A RS P20120327 A RSP20120327 A RS P20120327A RS 52423 B RS52423 B RS 52423B
- Authority
- RS
- Serbia
- Prior art keywords
- agomelatine
- production
- expressed
- formula
- crystal form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Kristalni oblik V agomelatina formule (I) :naznačen time što je dijagram difrakcije X zraka na dobijenom prašku kako sledi, a što je mereno na difraktometru Siemens D5005 (bakarna antikatoda) i izraženo kao među-mrežna udaljenost d, ugao Bragg 2 teta i, relativni intenzitet (izražen u procentima u odnosu na najintenzivniju prugu):2-teta (°) exp. d (A) exp. Intenzitet (%)9,84 8,979 1712,40 7,134 1513,31 6,646 co15,14 5,848 1815,98 5,543 1816,62 5,329 1917,95 4,939 10018,88 4,697 6520,49 4,332 2420,99 4,228 3423,07 3,852 3923,44 3,792 3624,28 3,663 5825,10 3,545 1926,02 3,422 1526,82 3,322 1927,51 3,239 16Prijava sadrži još 5 patentnih zahteva.Crystalline form V of agomelatine of formula (I): characterized in that the X-ray diffraction pattern on the obtained powder is as follows, measured on a Siemens D5005 diffractometer (copper anticathode) and expressed as inter-network distance d, Bragg 2 theta angle i, relative intensity (expressed as a percentage of the most intense band): 2-theta (°) exp. d (A) exp. Intensity (%) 9,84 8,979 1712,40 7,134 1513,31 6,646 co15,14 5,848 1815,98 5,543 1816,62 5,329 1917,95 4,939 10018,88 4,697 6520,49 4,332 2420,99 4,228 3423,07 3,852 3923, 44 3,792 3624,28 3,663 5825,10 3,545 1926,02 3,422 1526,82 3,322 1927,51 3,239 16The application contains 5 more claims.
Description
NOVI KRISTALNI V OBLIK NEW CRYSTAL V SHAPE
AGOMELATINA, POSTUPAK ZA AGOMELATIN, PROCEDURE FOR
NJEGOVU PROIZVODNJU I ITS PRODUCTION AND
FARMACEUTSKE SMEŠE KOJE GA PHARMACEUTICAL MIXTURES THAT CONTAIN IT
SADRŽE CONTENTS
Ovaj pronalazak se odnosi na novi oblik kristalnog V agomelatina ili A/-[2-(7-metoksi-1-naftil)etil]acetamida koji ima formulu (I): This invention relates to a new form of crystalline V agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide having the formula (I):
na postupak za njegovu proizvodnju, kao i na farmaceutske smeše koje ga sadrže. to the procedure for its production, as well as to the pharmaceutical mixtures containing it.
Agomelatin ili /V-[2-(7-metoksi-1-naftil)etil]acetamid ima korisna farmakološka svojstva. Agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide has beneficial pharmacological properties.
Ispoljava dejstvo dvostruke osobenosti, da je sa jedne strane agonist na receptorima melatoninergičnog sistema, a sa druge strane je antagonist receptora 5-HT2c- Ova svojstva mu daju aktivnost u centralnom nervnom sistemu i, preciznije, u lečenju opšte depresije, sezonskih depresija, poremećaja spavanja, kardiovaskularnih patologija, patologija digestivnog sistema, nesanica i umora kao posledica vremenske razlike, poremećaja apetita i gojaznosti. It exhibits the effect of a double peculiarity, that on the one hand it is an agonist on the receptors of the melatoninergic system, and on the other hand it is an antagonist of the 5-HT2c receptor. These properties give it activity in the central nervous system and, more precisely, in the treatment of general depression, seasonal depression, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue as a result of time difference, appetite disorders and obesity.
Agomelatin, njegova proizvodnja i njegova upotreba u terapeutske svrhe, opisani su u evropskom patentu EP 0 447 285. Agomelatine, its production and its use for therapeutic purposes are described in European patent EP 0 447 285.
Za procenu farmaceutske koristi od ovog jedinjenja, važno je njegovo dobijanje u vidu proizvoda odlične čistoće, a pre svega, u obliku savršene reproducibilnosti, koji ispoljava potrebna svojstva rastvorljivosti i olakšanog formulisanja čime omogućava produženo čuvanje bez posebnih uslova temperature, svetlosti, vlažnosti ili protoka kiseonika. To assess the pharmaceutical benefits of this compound, it is important to obtain it in the form of a product of excellent purity, and above all, in the form of perfect reproducibility, which exhibits the necessary properties of solubility and easy formulation, which allows for prolonged storage without special conditions of temperature, light, humidity or oxygen flow.
Patent EP 0 447 285 opisuje pristup od osam etapa do agomelatina, počevši od 7-metoksi-1-tetralona. Međutim, ovaj dokument ne precizira uslove dobijanja agomelatina u vidu jedne forme koja ispoljava svoje karakteristike na reproducibilan način. Zahtevalac sada ističe postupak dobijanja agomelatina u vidu kristalne forme koja je dobro definisana, savršeno reproducibilna i koja ispoljava korisne osobine dobrog rastvaranja i lakog formulisanja. EP 0 447 285 describes an eight-step approach to agomelatine, starting with 7-methoxy-1-tetralone. However, this document does not specify the conditions for obtaining agomelatine in the form of a single form that exhibits its characteristics in a reproducible manner. The applicant now highlights the process of obtaining agomelatine in the form of a crystalline form which is well defined, perfectly reproducible and which exhibits the useful properties of good dissolution and easy formulation.
Preciznije, ovaj pronalazak se odnosi na kristalni oblik V jedinjenja formule (I), koji je opisan dijagramom difrakcije X zraka praška, koji je izmeren na difraktometru Siemens D5005 (bakarna antikatoda) i izražen kao među-mrežna udaljenost d, ugao Bragg 2 teta i, relativni intenzitet (izražen u procentima u odnosu na najintenzivniju prugu): More specifically, this invention relates to the crystalline form V of the compound of formula (I), which is described by the X-ray powder diffraction pattern, which was measured on a Siemens D5005 diffractometer (copper anticathode) and expressed as inter-lattice distance d, Bragg angle 2 theta i, relative intensity (expressed as a percentage of the most intense line):
Pronalazak se, isto tako, odnosi na postupak za proizvodnju kristalnog V oblika jedinjenja formule (I), koji se odlikuje time što se agomelatin podvrgava mehaničkom mlevenju, nazvanom « visoko energetsko ». The invention also relates to the process for the production of the crystalline V form of the compound of formula (I), which is characterized by the fact that agomelatine is subjected to mechanical grinding, called "high energy".
Tokom postupka kristalizacije koji je u skladu sa pronalaskom, može se koristiti jedinjenje formule (I) koje je dobijeno ma kojim postupkom. During the crystallization process according to the invention, the compound of formula (I) obtained by any process can be used.
Pronalazak se, isto tako, odnosi na drugi postupak za proizvodnju kristalnog V oblika jedinjenja formule (I), koji se odlikuje time što se agomelatin greje sve dok se ne završi spajanje, zatim se ostavlja na temperaturi sredine i istovremeno se dodaje veoma mala količina kristalnog V oblika jedinjenja formule (I) koji je pripremljen svež, a zatim se ostavlja da se hladi sve dok se ne završi kristalizacija. The invention also relates to another process for the production of the crystalline V-form of the compound of formula (I), which is characterized by the fact that agomelatine is heated until the coupling is complete, then left at ambient temperature and at the same time a very small amount of the crystalline V-form of the compound of formula (I) is added, which is prepared fresh, and then allowed to cool until the crystallization is completed.
Poželjno, tokom ovog drugog postupka kristalizacije koji je u skladu sa pronalaskom, agomelatin će se topiti na 110°C. Preferably, during this second crystallization process according to the invention, the agomelatine will melt at 110°C.
Količina kristalnog V oblika koji se dodaje u toku ovog drugog postupka kristalizacije koji je u skladu sa pronalaskom, poželjno će biti između 1/100 do 1/50 težine agomelatina. The amount of crystalline V form added during this second crystallization process according to the invention will preferably be between 1/100 to 1/50 of the weight of agomelatine.
U toku ovog drugog postupka kristalizacije koji je u skladu sa pronalaskom, može se koristiti jedinjenje formule (I) dobijeno ma kojim postupkom. In the course of this second crystallization process which is in accordance with the invention, the compound of formula (I) obtained by any process can be used.
Dobijanje ove kristalne forme ima prednost što omogućava proizvodnju farmaceutskih formulacija koje imaju stalan i reproducibilan sastav, a ispoljavaju posebno korisna svojstva pri rastvaranju, što je naročito važno zbog toga što su ove formulacije namenjene oralnom primenjivanju. Obtaining this crystalline form has the advantage that it enables the production of pharmaceutical formulations that have a constant and reproducible composition, and exhibit particularly useful dissolution properties, which is particularly important because these formulations are intended for oral administration.
Farmakološko ispitivanje ovako dobijene forme V pokazalo je njenu značajnu aktivnost u centralnom nervnom sistemu, kao i na mikrocirkulaciju što omogućava njeno korišćenje za lečenje: stresa, poremećaja spavanja, anksioznosti, opšte depresije, sezonskih depresija, kardiovaskularnih patologija, patologija digestivnog sistema, nesanice i umora kao posledice vremenskih razlika, šizofrenije, napada panike, melanholije, poremećaja apetita, gojaznosti, nesanice, bola, psihotičnih poremećaja, epilepsije, dijabetesa, Parkinsonove bolesti, senilne demencije, raznih poremećaja koji su posledica normalnog ili patološkog starenja, migrene, gubitka pamćenja, Alchajmerove bolesti, kao i za poremećaje cerebralne cirkulacije. U drugom domenu aktivnosti, moguće je kristalnu formu V agomelatina korititi za tretman seksualnih disfunkcionalnosti, kao inhibitora ovulacije, imunomodulatora u tretmanu kancera. Pharmacological examination of the obtained form V showed its significant activity in the central nervous system, as well as on the microcirculation, which allows its use for the treatment of: stress, sleep disorders, anxiety, general depression, seasonal depression, cardiovascular pathologies, digestive system pathologies, insomnia and fatigue as a result of time differences, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, pain, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders resulting from normal or pathological aging, migraine, memory loss, Alzheimer's disease, as well as cerebral circulation disorders. In another domain of activity, it is possible to use the crystalline form of agomelatine V for the treatment of sexual dysfunctions, as an ovulation inhibitor, immunomodulator in the treatment of cancer.
Kristalni V oblik agomelatina, biće pre svega korišćen za lečenje opšte depresije, sezonskih depresija, poremećaja spavanja, kardiovaskularnih patologija, patologija digestivnog sistema, nesanica i umora kao posledica vremenske razlike, poremećaja apetita i gojaznosti. The crystalline V form of agomelatine will primarily be used for the treatment of general depression, seasonal depression, sleep disorders, cardiovascular pathologies, digestive system pathologies, insomnia and fatigue as a result of time difference, appetite disorders and obesity.
Pronalazak se, isto tako, odnosi na farmaceutske smeše koje kao aktivni princip sadrže kristalni V oblik jedinjenja formule (I) sa jednom ili više inertnih podloga, koje su netoksične i koje su odgovarajuće. Od farmaceutskih smeša koje su u skladu sa pronalaskom, mogu se naročito navesti one koje su pogodne za primenjivanje oralnim putem, parenteralnim (intravenskim ili subkutanim), nazalnim putem, kao jednostavne pilule ili dražeje, granule, sublingvalne pilule, želatinske kapsule, tablete, supozitorije, kremovi, masti, gelovi za kožu, injektabilni preparati, suspenzije za oralnu upotrebu i gume za žvakanje. The invention also relates to pharmaceutical mixtures which as active principle contain the crystalline V form of the compound of formula (I) with one or more inert bases, which are non-toxic and which are appropriate. Of the pharmaceutical mixtures according to the invention, those suitable for oral, parenteral (intravenous or subcutaneous), nasal administration, such as simple pills or dragees, granules, sublingual pills, gelatin capsules, tablets, suppositories, creams, ointments, skin gels, injectable preparations, suspensions for oral use and chewing gums, can be mentioned in particular.
Doziranje koje će biti delotvorno se podešava prema prirodi i težini bolesti, načinu primenjivanja, kao i starosti i težini pacijenta. Ovakvo doziranje varira od 0,1 mg do 1 g na dan u jednoj ili više doza. The dosage that will be effective is adjusted according to the nature and severity of the disease, the method of administration, as well as the age and weight of the patient. This dosage varies from 0.1 mg to 1 g per day in one or more doses.
Primeri u nastavku ilustruju pronalazak, ali ga ni na koji način ne ograničavaju. The following examples illustrate the invention, but do not limit it in any way.
Primer 1:Kristalni V oblik A/-[2-(7-metoksi-1-naftil)etil]acetamidaExample 1: Crystalline form V of A/-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
100 g A/-[2-(7-metoksi-1-naftil)etil]acetamida je stavljeno u mehanički mlin tipa varioplanetarnog mlina u toku otprilike 6 sati i dobijena čvrsta masa je opisana pomoću dijagrama difrakcije X zraka na dobijenom prašku, što je mereno na difraktometru Siemens D5005 (bakarna antikatoda) i izraženo kao među-mrežna udaljenost d, ugao Bragg 2 teta i, relativni intenzitet (izražen u procentima u odnosu na najintenzivniju prugu): 100 g of A/-[2-(7-methoxy-1-naphthyl)ethyl]acetamide was placed in a mechanical mill of the varioplanetary mill type for approximately 6 hours and the resulting solid mass was described by X-ray diffraction pattern of the obtained powder, which was measured on a Siemens D5005 diffractometer (copper anticathode) and expressed as interlattice distance d, Bragg angle 2 theta i, relative intensity (expressed in percentages compared to the most intense streak):
Primer 2: Kristalni V oblik A/-[2-(7-metoksi-1-naftil)etil]acetamidaExample 2: Crystalline form V of N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
4 g de /V-[2-(7-metoksi-1-naftil)etil]acetamida je stavljeno u ventilirani sušionik na 110°C. Posle sat vremena na 110°C, proizvod je ohlađen do temperature sredine i zasejan sa 0,05 g kristalnog V oblika A/-[2-(7-metoksi-1-naftil)etil]acetamida koji strukturno čist i koji je dobijen pomoću visoko energetskog mlina. Posle 5 minuta, kristalizacija je završena i dobijena čvrsta masa je opisana pomoću dijagrama difrakcije X zraka na dobijenom prašku, što je mereno na difraktometru Siemens D5005 (bakarna antikatoda) i izraženo kao među-mrežna udaljenost d, ugao Bragg 2 teta i, relativni intenzitet (izražen u procentima u odnosu na najintenzivniju prugu): 4 g of N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide was placed in a ventilated dryer at 110°C. After one hour at 110° C., the product was cooled to ambient temperature and seeded with 0.05 g of structurally pure crystalline form V of A/-[2-(7-methoxy-1-naphthyl)ethyl]acetamide obtained using a high energy mill. After 5 minutes, the crystallization is complete and the resulting solid is described by X-ray diffraction pattern of the obtained powder, which was measured on a Siemens D5005 diffractometer (copper anticathode) and expressed as inter-lattice distance d, Bragg angle 2 theta i, relative intensity (expressed as a percentage of the most intense line):
Primer 3: Farmaceutska smešaExample 3: Pharmaceutical composition
Formula za izradu 1000 tableta u dozi od po 25 mg : Formula for making 1000 tablets in a dose of 25 mg each:
Primer 4:Farmaceutska smešaFormula za izradu 1000 tableta u dozi od po 25 mg : Example 4: Pharmaceutical mixture Formula for making 1000 tablets in a dose of 25 mg each:
Claims (2)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508278A FR2889523B1 (en) | 2005-08-03 | 2005-08-03 | NOVEL CRYSTALLINE FORM V OF AGOMELATIN, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS52423B true RS52423B (en) | 2013-02-28 |
Family
ID=36581629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20120327A RS52423B (en) | 2005-08-03 | 2006-08-02 | THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT |
Country Status (38)
| Country | Link |
|---|---|
| EP (2) | EP2277857A3 (en) |
| JP (1) | JP4575337B2 (en) |
| CN (1) | CN100448843C (en) |
| AP (1) | AP2486A (en) |
| AR (1) | AR057715A1 (en) |
| AU (1) | AU2006203342B2 (en) |
| BR (1) | BRPI0603059A (en) |
| CA (1) | CA2555115C (en) |
| CR (1) | CR8529A (en) |
| CU (1) | CU20060153A7 (en) |
| CY (1) | CY1113011T1 (en) |
| DK (1) | DK1752443T3 (en) |
| EA (1) | EA011030B1 (en) |
| EC (1) | ECSP066715A (en) |
| ES (1) | ES2391406T3 (en) |
| FR (1) | FR2889523B1 (en) |
| GT (1) | GT200600346A (en) |
| HR (1) | HRP20120779T1 (en) |
| IL (1) | IL177173A (en) |
| JO (1) | JO2793B1 (en) |
| MA (1) | MA28451B1 (en) |
| ME (1) | ME02026B (en) |
| MX (1) | MXPA06008789A (en) |
| MY (1) | MY139902A (en) |
| NO (1) | NO336967B1 (en) |
| NZ (1) | NZ548864A (en) |
| PE (1) | PE20070365A1 (en) |
| PL (1) | PL1752443T3 (en) |
| PT (1) | PT1752443E (en) |
| PY (1) | PY0622199A (en) |
| RS (1) | RS52423B (en) |
| SA (1) | SA06270255B1 (en) |
| SG (1) | SG130110A1 (en) |
| SI (1) | SI1752443T1 (en) |
| TW (1) | TWI359128B (en) |
| UA (1) | UA83720C2 (en) |
| WO (1) | WO2007015004A2 (en) |
| ZA (1) | ZA200606453B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2934856B1 (en) * | 2008-08-05 | 2010-08-13 | Servier Lab | NEW PROCESS FOR OBTAINING THE V-CRYSTALLINE FORM OF AGOMELATIN |
| CN101481321B (en) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | Agomelatine hydrogen halide complex and preparation method thereof |
| CN101585779B (en) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | New crystal form of Agomelatine, preparation method and use thereof |
| WO2011006387A1 (en) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | Process for preparing agomelatine, crystals of agomelatine and preparing process thereof |
| CN102001959B (en) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | Medicinal crystal as well as preparation method and application thereof |
| CN102050755B (en) * | 2009-10-29 | 2014-11-05 | 重庆医药工业研究院有限责任公司 | Novel agomelatine crystal forms and preparation methods of agomelatine crystal forms |
| CN101781226B (en) * | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | Agomelatine and medicine composition thereof |
| WO2011154140A2 (en) | 2010-06-10 | 2011-12-15 | Gador S.A. | New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide and new crystalline form |
| CN102000583B (en) * | 2010-11-18 | 2012-08-15 | 烟台万华聚氨酯股份有限公司 | Catalyst for preparing chlorine by oxidizing hydrogen chloride and preparation method thereof |
| CN102690210A (en) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | Novel crystal form VII of agomelatine, preparation method and application thereof and pharmaceutical composition containing the same |
| CN102690209A (en) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | Mixed crystal of agomelatine (form-VIII), preparation method and application thereof and pharmaceutical composition containing the same |
| JP6212485B2 (en) * | 2011-06-02 | 2017-10-11 | キノイン・ゼー・エル・テー | New production method of prostaglandin amide |
| FR2978916B1 (en) | 2011-08-10 | 2013-07-26 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
| EP2771312B1 (en) | 2011-11-30 | 2017-05-31 | ratiopharm GmbH | Agomelatine-urea complex and crystalline forms thereof |
| CZ2012108A3 (en) | 2012-02-15 | 2013-02-27 | Zentiva Ks | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
| CN103360275B (en) * | 2012-03-30 | 2015-04-22 | 上海创诺制药有限公司 | Method for preparing agomelatine I-type crystal |
| WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
| FR3001894A1 (en) | 2013-02-08 | 2014-08-15 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
| EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| ES2645223T3 (en) | 2013-06-06 | 2017-12-04 | Zentiva, K.S. | Agomelatine formulations comprising agomelatine in the form of co-crystals |
| CZ2013621A3 (en) | 2013-08-13 | 2015-02-25 | Zentiva, K.S. | Agomelatine thermodynamically stable congealed solution for use in pharmaceutical formulation |
| WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
| FR3033131B1 (en) | 2015-02-26 | 2017-11-17 | Servitronique | SLIDE FOR ITS SLIDING ADJUSTMENT SYSTEMS AND ASSEMBLY METHOD |
| ES2959460T3 (en) | 2015-03-31 | 2024-02-26 | Fis Fabbrica Italiana Sintetici Spa | solid form of agomelatine |
| EP3466923A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Process for the preparation of agomelatine in crystalline form |
| EP3466413A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
| CN113952323A (en) * | 2021-12-10 | 2022-01-21 | 李甜 | Application of agomelatine in inhibition of Ube2c protein expression |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (en) * | 1990-02-27 | 1993-12-31 | Adir Cie | NOVEL DERIVATIVES WITH NAPHTHALENIC STRUCTURE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| FR2866336B1 (en) * | 2004-02-13 | 2006-03-24 | Servier Lab | NOVEL PROCESS FOR THE SYNTHESIS OF (7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL) ACETONITRILE AND APPLICATION TO THE SYNTHESIS OF AGOMELATIN |
| FR2866335B1 (en) * | 2004-02-13 | 2006-05-26 | Servier Lab | NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN |
-
2005
- 2005-08-03 FR FR0508278A patent/FR2889523B1/en not_active Expired - Fee Related
-
2006
- 2006-07-19 PE PE2006000868A patent/PE20070365A1/en not_active Application Discontinuation
- 2006-07-20 EC EC2006006715A patent/ECSP066715A/es unknown
- 2006-07-24 AP AP2006003695A patent/AP2486A/en active
- 2006-07-24 CR CR8529A patent/CR8529A/en unknown
- 2006-07-24 MA MA29212A patent/MA28451B1/en unknown
- 2006-07-24 JO JO2006247A patent/JO2793B1/en active
- 2006-07-31 GT GT200600346A patent/GT200600346A/en unknown
- 2006-07-31 IL IL177173A patent/IL177173A/en active IP Right Grant
- 2006-08-01 SA SA06270255A patent/SA06270255B1/en unknown
- 2006-08-01 NZ NZ548864A patent/NZ548864A/en not_active IP Right Cessation
- 2006-08-01 SG SG200605171-8A patent/SG130110A1/en unknown
- 2006-08-02 PY PY200600622199A patent/PY0622199A/en unknown
- 2006-08-02 RS RS20120327A patent/RS52423B/en unknown
- 2006-08-02 DK DK06291251.4T patent/DK1752443T3/en active
- 2006-08-02 WO PCT/FR2006/001869 patent/WO2007015004A2/en not_active Ceased
- 2006-08-02 NO NO20063517A patent/NO336967B1/en unknown
- 2006-08-02 ME MEP-2012-327A patent/ME02026B/en unknown
- 2006-08-02 PT PT06291251T patent/PT1752443E/en unknown
- 2006-08-02 ES ES06291251T patent/ES2391406T3/en active Active
- 2006-08-02 SI SI200631396T patent/SI1752443T1/en unknown
- 2006-08-02 EP EP10011469A patent/EP2277857A3/en not_active Withdrawn
- 2006-08-02 BR BRPI0603059-9A patent/BRPI0603059A/en not_active Application Discontinuation
- 2006-08-02 CU CU20060153A patent/CU20060153A7/en unknown
- 2006-08-02 UA UAA200608689A patent/UA83720C2/en unknown
- 2006-08-02 PL PL06291251T patent/PL1752443T3/en unknown
- 2006-08-02 AR ARP060103366A patent/AR057715A1/en not_active Application Discontinuation
- 2006-08-02 TW TW095128302A patent/TWI359128B/en not_active IP Right Cessation
- 2006-08-02 EA EA200601273A patent/EA011030B1/en unknown
- 2006-08-02 EP EP06291251A patent/EP1752443B1/en active Active
- 2006-08-02 MY MYPI20063736A patent/MY139902A/en unknown
- 2006-08-03 MX MXPA06008789A patent/MXPA06008789A/en active IP Right Grant
- 2006-08-03 JP JP2006211622A patent/JP4575337B2/en not_active Expired - Fee Related
- 2006-08-03 AU AU2006203342A patent/AU2006203342B2/en not_active Ceased
- 2006-08-03 ZA ZA200606453A patent/ZA200606453B/en unknown
- 2006-08-03 CA CA2555115A patent/CA2555115C/en active Active
- 2006-08-03 CN CNB2006101083952A patent/CN100448843C/en not_active Expired - Fee Related
-
2012
- 2012-07-18 CY CY20121100635T patent/CY1113011T1/en unknown
- 2012-10-01 HR HRP20120779TT patent/HRP20120779T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS52423B (en) | THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT | |
| ME02024B (en) | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors | |
| AU2006203340B2 (en) | New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| RS55499B1 (en) | THE NEW CRYSTAL FORM III OF AGOMELATIN, THE PROCEDURE OF ITS MANUFACTURING AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| RS55316B1 (en) | THE NEW FORM OF CRYSTAL VI AGOMELATINE, THE PREPARATION PROCEDURE AND ITS PHARMACEUTICAL COMPOSITION | |
| US7910625B2 (en) | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| US20100063158A1 (en) | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| US7358395B2 (en) | Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| KR100904116B1 (en) | V crystal form of agomelatine, preparation method thereof and pharmaceutical composition containing same | |
| HK1098129B (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HK1098130B (en) | New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HK1098128B (en) | New crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HK1131777B (en) | Crystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| KR20070017020A (en) | Crystalline Form IV of Agomelatine, Methods for Making the Same and Pharmaceutical Compositions Containing the Same | |
| KR20070017019A (en) | Crystalline Form III of agomelatine, methods for preparing the same, and pharmaceutical compositions containing the same |